Information Provided By: 
Fly News Breaks for March 7, 2016
SGMO
Mar 7, 2016 | 08:46 EDT
Janney Capital analyst Roy Buchanan says that updated mouse data for Sangamo's in vivo protein replacement platform, or IVPRP, for treating MPS I and II continue to support expectations for efficacy and that the brain data is encouraging and adds additional support. The analyst notes, however, that he hasn't increased his probability of success for the program on this data, as much of it had been presented previously. Buchanan keeps a Buy rating and $15 fair value estimate on Sangamo shares.
News For SGMO From the Last 2 Days
There are no results for your query SGMO
